MedTrace Logo

Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)

NCT00149227 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3031

Last updated 2012-12-12

Study results available
· View outcomes & findings →

Summary

The KYOTO HEART Study is to assess the add-on effect of valsartan, an Angiotensin-Receptor Blocker, on top of the conventional treatment in high risk patients in Japan with hypertension in terms of the morbidity and mortality.

Conditions

Interventions

DRUG

Valsartan

Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.

DRUG

Non-ARB

'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs

Sponsors & Collaborators

  • Kyoto Prefectural University of Medicine

    lead OTHER

Principal Investigators

  • Hiroaki Matsubara, MD,PhD · Kyoto Prefectural University of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00149227 on ClinicalTrials.gov